Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial

Wannigama et al., eClinicalMedicine, 10.1016/j.eclinm.2024.102517, NCT05087381, Mar 2024
Early treatmentRCT · 995 patients · Thailand · Oct 2021 – Jun 2022
Bromhexine for COVID-19
Wannigama et al. eClinicalMedicine, 10.1016/j.eclinm.2024.102517
RCT 995 outpatients showing significantly lower progression with early treatment within 48 hours using fluvoxamine, fluvoxamine+bromhexine, fluvoxamine+cyproheptadine, and niclosamide+bromhexine.
70% of patients received treatment within 12 hours of symptom onset.
Treatments groups showed significantly lower long COVID (PASC). The combined treatment groups showed significantly lower viral load as early as day 3. The 3 combination arms were superior to fluvoxamine alone.
The study was open-label. 593 out of 1,900 randomized participants did not receive the treatment, mostly due to inability to confirm eligibility, however baseline characteristics were similar for these patients.
There was a very high hospitalization rate in the control arm. Authors note that the majority of cases were mild - the threshold for hospitalization may have been very low (in some places/times all cases were hospitalized). Authors also note that the patients requiring high flow oxygen all had the delta/alpha variants, and that the population has many health disparities.
Publication was over 500 days after the 90 day followup.
Bromhexine efficacy may vary depending on the degree of TMPRSS-dependent fusion for different variants1,2.
Study covers niclosamide, TMPRSS2 inhibitors, bromhexine, and fluvoxamine.
OutcomeImprovementEffect · pTreatmentControl
risk of mechanical ventilation 98.5% lower · RR 0.02 · p < 0.001*** 98.5% lowerRR 0.02p < 0.001*** 0 of 350 (0.0%) 32 of 336 (9.5%) treatment 0 of 350 (0.0%), control 32 of 336 (9.5%)combined bromhexine armsNNT 10continuity correction due to zero eventsday 28
risk of mechanical ventilation 98.2% lower · RR 0.02 · p < 0.001*** 98.2% lowerRR 0.02p < 0.001*** 0 of 350 (0.0%) 27 of 336 (8.0%) treatment 0 of 350 (0.0%), control 27 of 336 (8.0%)combined bromhexine armsNNT 12continuity correction due to zero eventsday 14
risk of mechanical ventilation 97.5% lower · RR 0.03 · p < 0.001*** 97.5% lowerRR 0.03p < 0.001*** 0 of 350 (0.0%) 19 of 336 (5.7%) treatment 0 of 350 (0.0%), control 19 of 336 (5.7%)combined bromhexine armsNNT 18continuity correction due to zero eventsday 9
risk of oxygen therapy 99.7% lower · RR 0.00 · p < 0.001*** 99.7% lowerRR 0.00p < 0.001*** 0 of 350 (0.0%) 171 of 336 (50.9%) treatment 0 of 350 (0.0%), control 171 of 336 (50.9%)combined bromhexine armsNNT 2.0continuity correction due to zero eventsday 28
risk of oxygen therapy 99.7% lower · RR 0.00 · p < 0.001*** 99.7% lowerRR 0.00p < 0.001*** 0 of 350 (0.0%) 150 of 336 (44.6%) treatment 0 of 350 (0.0%), control 150 of 336 (44.6%)combined bromhexine armsNNT 2.2continuity correction due to zero eventsday 14
risk of oxygen therapy 99.6% lower · RR 0.00 · p < 0.001*** 99.6% lowerRR 0.00p < 0.001*** 0 of 350 (0.0%) 117 of 336 (34.8%) treatment 0 of 350 (0.0%), control 117 of 336 (34.8%)combined bromhexine armsNNT 2.9continuity correction due to zero eventsday 9
risk of hospitalization 98.5% lower · RR 0.02 · p < 0.001*** 98.5% lowerRR 0.02p < 0.001*** 0 of 350 (0.0%) 32 of 336 (9.5%) treatment 0 of 350 (0.0%), control 32 of 336 (9.5%)combined bromhexine armsNNT 10continuity correction due to zero eventsday 28
risk of hospitalization 98.2% lower · RR 0.02 · p < 0.001*** 98.2% lowerRR 0.02p < 0.001*** 0 of 350 (0.0%) 27 of 336 (8.0%) treatment 0 of 350 (0.0%), control 27 of 336 (8.0%)combined bromhexine armsNNT 12continuity correction due to zero eventsday 14
risk of hospitalization 97.5% lower · RR 0.03 · p < 0.001*** 97.5% lowerRR 0.03p < 0.001*** 0 of 350 (0.0%) 19 of 336 (5.7%) treatment 0 of 350 (0.0%), control 19 of 336 (5.7%)combined bromhexine armsNNT 18continuity correction due to zero eventsday 9
risk of long COVID 55.1% lower · RR 0.45 · p < 0.001*** 55.1% lowerRR 0.45p < 0.001*** 157 of 350 (44.9%) 336 of 336 (100.0%) treatment 157 of 350 (44.9%), control 336 of 336 (100.0%)combined bromhexine armsNNT 1.8day 90

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. *** p < 0.001

Wannigama et al., 14 Mar 2024, Randomized Controlled Trial, Thailand, peer-reviewed, 29 authors, study period 1 October, 2021 - 21 June, 2022, average treatment delay 0.5 days, this trial uses multiple treatments in the treatment arm (combined with fluvoxamine/niclosamide) - results of individual treatments may vary, trial NCT05087381 (history). Contact: Dhammika.L@chula.ac.th, Phatthranit.pha@mahidol.edu, gochi.akk@gmail.com.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 Thailand Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia CAR Chad Syria Thailand favored low-cost treatments.The average efficacy of treatments was high.Low-cost treatments improve early treatment, andprovide complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 Thailand Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan Egypt Nigeria Taiwan Fiji Zambia Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia CAR Chad Syria Thailand favored low-cost treatments.The average efficacy was high.Low-cost protocols improve early treatment,and add complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%